Article Text

Download PDFPDF

878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants
  1. Daniel Hirschhorn1,
  2. Sadna Budhu1,
  3. Lukas Kraehenbuehl2,
  4. Mathieu Gigoux1,
  5. David Schröder1,
  6. Andrew Chow1,
  7. Jacob M Ricca1,
  8. Billel Gasmi1,
  9. Olivier De Henau1,
  10. Levi Mark B Mangarin1,
  11. Yanyun Li3,
  12. Anne-Laure Flamar1,
  13. Heyjin Choi1,
  14. Czrina A Cortez1,
  15. Cailian Liu1,
  16. Aliya Holland1,
  17. Sara Schad1,
  18. Isabell Schulze1,
  19. Linda Hamadene1,
  20. Allison Betof Warner1,
  21. Travis Hollmann3,
  22. Arshi Arora4,
  23. Katherine S Panageas4,
  24. Rebekka Duhen5,
  25. Andrew D Weinberg5,
  26. Gabrielle A Rizzuto6,
  27. Christine N Spencer7,
  28. David Ng8,
  29. Xue-Yan He8,
  30. Jean Albrengues8,
  31. David Redmond9,
  32. Mikala Egeblad8,
  33. Jedd D Wolchok1 and
  34. Taha Merghoub1
  1. 1Weill Cornell Medical and Graduate Schools, New York, New York, USA
  2. 2Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
  3. 3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  4. 4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
  5. 5Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
  6. 6Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  7. 7Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
  8. 8Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA
  9. 9Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, New York, NY, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background The immune system eliminates cancers in the early stages of malignant transformation. However, the presence of immune cells exerts selective pressure on tumors, which can result in tumor editing, leading to the development of immune escape variants. A common occurrence in cancers is the loss of antigenic protein expression on tumor cells, which creates antigenic heterogeneity and makes tumors resistant to immunotherapies such as adoptive cell therapies. Consequently, it is necessary to study and engage multiple components of the immune system in immunotherapeutic interventions to effectively eradicate heterogeneous tumors.

Methods This study aimed to assess the efficacy of a combination therapy involving CD4+ T cells recognizing the melanoma antigen Trp1 in conjunction with either OX40 co-stimulation or CTLA-4 blockade (ICB) for eradicating advanced melanomas containing antigen escape variants in preclinical mouse models.

Results The combination therapy successfully eliminated antigen-loss variant clones in a preclinical mouse model of melanoma with heterogeneous Trp1 expression. Mechanistically, tumors from treated mice exhibited significant infiltration of activated neutrophils, which was also observed in cancer patients following ICB therapy. Depletion of neutrophils in our preclinical melanoma model of antigenic heterogeneity abolished the therapeutic efficacy of the combination treatment. Our findings revealed the importance of inducible nitric oxide synthase in neutrophil-mediated elimination of escape variants. Furthermore, neutrophils derived from tumors of treated mice exhibited a distinct transcriptomic and protein surface signature associated with anti-tumorigenic properties. This anti-tumorigenic neutrophil signature was also observed in tumors from melanoma patients treated with ICB that experienced survival benefits.

Conclusions Our findings demonstrate the interplay between T cells, which initiate the anti-tumor immune response, and neutrophils, which contribute to the elimination of tumor antigen loss variants in later stages. These insights underscore the potential of combined therapies in overcoming clonal escape variants in melanoma and provide valuable information on the role of neutrophils in tumor eradication when employing T cell immunotherapies.

Ethics Approval All tissues collected at MSKCC following study protocol approval by the MSKCC Institutional Review Board. Informed consent was obtained for all patients. The study was in strict compliance with all institutional ethical regulations.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.